Chemo after surgery for recurrent nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a chemotherapy combination (TC) given after surgery for nasopharyngeal cancer that has come back locally. The goal is to see if this treatment helps prevent the cancer from returning again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recurrent nasopharyngeal cancer that can be removed with surgery, specifically stages rT1, rT2, or rT3 in the nasopharynx or neck lymph nodes (rN1-3).
- It has been at least 6 months since you last received radiation therapy.
- You are between 18 and 70 years old.
- Your overall health is good (ECOG score 0 or 1), and your blood counts, liver, and kidney function are within normal limits.
- You are not pregnant or breastfeeding, and you agree to use birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (toripalimab), chemotherapy, radiation, and omega-3 supplements for people with locally advanced nasopharyngeal cancer that hasn't spread. The goal is to see if this approach works better than standard treatment.
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
This trial tests giving chemotherapy before and after surgery for people whose nasal cancer has come back. The goal is to see if this approach helps remove the cancer more effectively and prevents it from returning again.
This study looks at whether adding chemo-immunotherapy after surgery is better than surgery alone for patients whose nasopharyngeal cancer has returned but is still in early stages. It may help prevent the cancer from coming back again.
This trial tests whether giving chemotherapy plus immunotherapy (pembrolizumab) before and after surgery can help people whose nasopharyngeal cancer has come back in the same area (locally recurrent). The goal is to see if this approach improves outcomes.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people whose nasopharyngeal cancer has come back or spread. It is for those who haven't yet received other treatments for this advanced stage.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.